Showing results (11-20 of 120) with videos related to
Sort By:
Pageof 12
International Journal of Antimicrobial Agents|February 19, 2002
Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infectionsKurt G Naber, Orlin Savov, Hans C SalmenGMS Infectious Diseases|February 2, 2022
Urinary tract infections in patients with renal insufficiency and dialysis - epidemiology, pathogenesis, clinical symptoms, diagnosis and treatmentJürgen E Scherberich, Reinhard Fünfstück, Kurt G NaberAktuelle Urologie|April 21, 2017
[In-vitro activity of mecillinam against urine isolates of Escherichia coli from outpatient departments in Germany]Michael Kresken, Barbara Körber-Irrgang, Kurt G NaberWorld Journal of Urology|January 20, 2006
Chlamydial infections in urologyFlorian M E Wagenlehner, Wolfgang Weidner, Kurt G NaberEuropean Urology|July 4, 2020
The EAU and AUA/CUA/SUFU Guidelines on Recurrent Urinary Tract Infections: What is the Difference?Kurt G Naber, Gernot Bonkat, Florian M E WagenlehnerInternational Journal of Antimicrobial Agents|October 18, 2011
Antibiotic treatment of uncomplicated urinary tract infection in premenopausal womenKurt G Naber, Björn Wullt, Florian M E WagenlehnerGMS Infectious Diseases|December 10, 2020
Biomarkers in urinary tract infections - which ones are suitable for diagnostics and follow-up?József Horváth, Björn Wullt, Kurt G Naber, et al.Expert Opinion on Emerging Drugs|June 7, 2005
Emerging drugs for bacterial urinary tract infectionsFlorian M E Wagenlehner, Wolfgang Weidner, Kurt G NaberClinical Pharmacokinetics|March 23, 2007
Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsisFlorian M E Wagenlehner, Wolfgang Weidner, Kurt G NaberExpert Opinion on Pharmacotherapy|August 10, 2007
Therapy for prostatitis, with emphasis on bacterial prostatitisFlorian M E Wagenlehner, Wolfgang Weidner, Kurt G NaberPageof 12